期刊文献+

配体—受体系统介导的药物靶向性研究进展 被引量:5

Progress in Ligand-Receptor System Mediated Drug Targeting
下载PDF
导出
摘要 配体 受体系统介导的药物靶向性研究在过去 10年中得到了很大的发展。配体介导的主动靶向能够将药物定向运送到血管腔隙、细胞表面和细胞内。使用的配体包括抗体、蛋白质、肽、脂蛋白、糖类以及其他内源性分子。文章介绍了药物靶向研究中使用的多种配体 受体系统 ,包括运铁蛋白受体、脂蛋白受体、细胞因子受体、凝集素受体、清道夫受体和叶酸受体。 The rapid progress in has developed in past decade. ligand-receptor system mediated drug targeting. Ligand mediated active targeting has been shown to be a novel method in targeting vascular compartment, cellular or intracellular levels. The common ligands include antibodies, proteins, Peptides, lipoproteins, carbohydrates, and endogenous molecules. This review describe various ligand-receptor systems that have been investigated for drug targeting. These receptors are transferrin receptors, lipoprotein receptors, cytokine receptors, lectin receptors, scavenger receptors, and folate receptors.
作者 谢云飞
出处 《药物生物技术》 CAS CSCD 2004年第2期130-134,共5页 Pharmaceutical Biotechnology
关键词 配体 受体 配体-受体介导 药物靶向 Ligand, Receptor, Ligand-receptor mediate, Drug targeting
  • 相关文献

参考文献29

  • 1管昌田,钟裕国.以NGA作为肝靶向药物载体的可行性研究[J].中华核医学杂志,1992,12(3):166-168. 被引量:8
  • 2Yang J C, Haworth L, Sherry R M, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer[J]. N Engl J Med,2003,349(5) : 427.
  • 3Veenendaal L M, Jin H, Ran S, et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors[J]. Proc Natl Acad Sci U S A, 2002,99(12),7866.
  • 4Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibilor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth[J]. Br J Cancer, 2001,85(12) : 2010.
  • 5Giles F J, Cooper M A, Silverman L, et al. Phase Ⅱ study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases[J]. Cancer, 2003,97(8) : 1920.
  • 6Kawakami S, Wong J, Sato A, et al. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice[J]. Biochim Biophys Acta, 2000, 1524(2-3):258.
  • 7Hashida M, Nishikawa M, Yamashita F, et al. Cell-specific delivery of genes with glycosylated carriers[J]. Adv Drug Deliv Rev, 2001,52(3) : 187.
  • 8Copland M J, Baird M A, Rades T, et al. Liposomal delivery of antigen to human dendritic cells[J]. Vaccine, 2003,21(910) :883.
  • 9Dumont S, Muller C D, Schuber F, et al. Antitumoral properties and reduced toxicity of LPS targeted to macrophages via normal or mannosylated liposomes [ J ]. Anticancer Res,1990,10(1):155.
  • 10Yamasaki Y, Sumimoto K, Nishikawa M, et al. Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors., importance of molecular size and negative charge density for in vivo recognition by receptors[J].J Pharmacol Exp Ther, 2002,301(2) :467.

二级参考文献2

  • 1管昌田,中华核医学杂志,1991年,11卷,232页
  • 2管昌田,国外医学放射医学核医学分册,1990年,14卷,127页

共引文献7

同被引文献66

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部